Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MORF

Morphic Holding Inc

Dec 08 • 04:00PM ET

27.17

Dollar change +0.58
Percentage change 2.18	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.18	Insider Own	23.08%	Shs Outstand	38.58M	Perf Week	11.31%
Market Cap	1.35B	Forward P/E	-	EPS next Y	-3.87	Insider Trans	-0.27%	Shs Float	38.26M	Perf Month	26.20%
Income	-135.74M	PEG	-	EPS next Q	-0.86	Inst Own	81.51%	Short Float / Ratio	15.98% / 5.41	Perf Quarter	-49.88%
Sales	6.66M	P/S	202.92	EPS this Y	-123.84%	Inst Trans	-1.49%	Short Interest	6.11M	Perf Half Y	-55.99%
Book/sh	14.54	P/B	1.87	EPS next Y	-11.53%	ROA	-23.97%	Target Price	57.89	Perf Year	1.87%
Cash/sh	14.58	P/C	1.86	EPS next 5Y	-	ROE	-24.95%	52W Range	19.34 - 63.08	Perf YTD	1.57%
Dividend	-	P/FCF	-	EPS past 5Y	-21.85%	ROI	-18.74%	52W High	-56.93%	Beta	1.37
Dividend %	-	Quick Ratio	38.25	Sales past 5Y	154.41%	Gross Margin	84.16%	52W Low	40.45%	ATR	1.41
Employees	102	Current Ratio	38.25	Sales Q/Q	-100.00%	Oper. Margin	-2341.29%	RSI (14)	68.01	Volatility	5.09% 5.72%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	6.31%	Profit Margin	-2039.32%	Rel Volume	0.61	Prev Close	26.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 03 BMO	Payout	-	Avg Volume	1.13M	Price	27.17
Recom	1.36	SMA20	15.75%	SMA50	22.22%	SMA200	-37.81%	Volume	694,396	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-23	Initiated	Citigroup	Buy	$46
Sep-25-23	Reiterated	Stifel	Hold	$61 → $33
Sep-25-23	Downgrade	BTIG Research	Buy → Neutral
Aug-09-23	Downgrade	Stifel	Buy → Hold	$69 → $61
Sep-07-22	Initiated	Stifel	Buy	$44
Jul-20-22	Initiated	SVB Leerink	Outperform	$45
Mar-31-22	Initiated	Canaccord Genuity	Buy	$68
Feb-11-22	Initiated	BTIG Research	Buy	$64
Dec-08-21	Initiated	Wells Fargo	Overweight	$81
Oct-26-20	Initiated	RBC Capital Mkts	Outperform	$35
Jul-22-19	Initiated	Wells Fargo	Outperform
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform	$30

Show Previous Ratings

Dec-01-23 03:59PM	Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors (Business Wire)
09:55AM	Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High? (Zacks)
Nov-15-23 09:55AM	Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet (Zacks)
Nov-10-23 08:00AM	Morphic to Present at November Investor Conferences (GlobeNewswire)
Nov-09-23 12:00PM	Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.27%
04:24PM	Loading…
Nov-06-23 04:24PM	Morphic Corporation: Company Investigated by the Portnoy Law Firm (GlobeNewswire) -6.20%
Nov-03-23 08:46AM	Morphic Holding Inc (MORF) Reports Q3 2023 Loss of $36.2 Million, Ends Quarter with $725. ... (GuruFocus.com) +8.20%
07:00AM	Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
Oct-09-23 08:00AM	Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set (GlobeNewswire)
Sep-28-23 06:27AM	The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan (American City Business Journals)
Sep-26-23 04:10PM	Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence (GlobeNewswire) -7.82%
Sep-25-23 04:08PM	The Surprise That Prompted Morphic Therapeutic To Dump 55% Over Two Days (Investor's Business Daily) -36.91%
12:58PM	Morphic Therapeutic stock nosedives on disappointing trial data (American City Business Journals)
Sep-22-23 05:30PM	Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023 (GlobeNewswire) -28.64%
Sep-09-23 01:01PM	Morphic Holding Inc CFO and COO Marc Schegerin Sells 20,000 Shares (GuruFocus.com)
08:00AM	Loading…
Aug-29-23 08:00AM	Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire) -6.63%
Aug-07-23 06:24AM	Morphic Holding, Inc.'s (NASDAQ:MORF) large institutional owners must be happy as stock continues to impress, up 4.4% over the past week (Simply Wall St.)
Aug-03-23 08:55AM	Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 (GlobeNewswire)
Jun-08-23 03:22PM	3 Stocks That Could Skyrocket by This Time Next Summer (InvestorPlace)
Jun-06-23 04:05PM	Morphic to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-26-23 03:31PM	Here's Why We're Not At All Concerned With Morphic Holding's (NASDAQ:MORF) Cash Burn Situation (Simply Wall St.)
May-22-23 05:23PM	Inside Scoop: 10 Mid-Cap Stocks with Recent Insider Purchases (Insider Monkey)
May-12-23 08:30AM	Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-11-23 08:00AM	Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis (GlobeNewswire)
May-07-23 07:40PM	Insiders Pour Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Steer Toward Them Too (TipRanks)
May-06-23 08:13AM	Morphic Holding Founder Acquires 16% More Stock \ (Simply Wall St.)
May-05-23 10:30AM	Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
09:23AM	Q1 2023 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
12:13AM	Loading…
May-03-23 12:13AM	Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering (GlobeNewswire) +5.57%
May-02-23 04:02PM	Morphic Therapeutic Announces Proposed Public Offering (GlobeNewswire)
Apr-30-23 08:10AM	What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-27-23 06:10AM	The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio (Zacks)
Apr-26-23 07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 11:54AM	Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars (Benzinga) +7.28%
08:15AM	Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures (GlobeNewswire)
06:59AM	Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
Apr-24-23 04:01PM	Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023 (GlobeNewswire)
Apr-18-23 10:56AM	Morphic Holding (NASDAQ:MORF) delivers shareholders strong 41% CAGR over 3 years, surging 20% in the last week alone (Simply Wall St.)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-18-23 08:29AM	Some Analysts Just Cut Their Morphic Holding, Inc. (NASDAQ:MORF) Estimates (Simply Wall St.)
Mar-03-23 09:05AM	Morphic to Present at TD Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-24-23 05:26AM	Morphic Holding Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Feb-23-23 08:00AM	Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 (GlobeNewswire)
Feb-15-23 09:04AM	Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF) (Simply Wall St.)
Feb-14-23 08:00AM	Morphic to Present at SVB Leerink Global Healthcare Conference (GlobeNewswire) +5.49%
Jan-26-23 05:54AM	The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug (American City Business Journals)
Jan-13-23 07:26AM	Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains? (Zacks)
Jan-05-23 09:09AM	Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 06:48AM	Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation (Simply Wall St.)
Nov-22-22 08:00AM	Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-09-22 08:00AM	Morphic Announces Participation in 2022 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 06:29AM	Industry Analysts Just Made An Upgrade To Their Morphic Holding, Inc. (NASDAQ:MORF) Revenue Forecasts (Simply Wall St.)
Nov-02-22 09:15AM	Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022 (GlobeNewswire)
Oct-28-22 12:07PM	Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance (Zacks) +7.22%
Oct-27-22 12:26PM	BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View (Zacks)
Oct-25-22 04:05PM	Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022 (GlobeNewswire) +9.13%
01:59PM	Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook (Zacks)
Oct-24-22 08:00AM	Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections (GlobeNewswire)
Oct-20-22 01:19PM	Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab (Zacks)
Oct-10-22 08:00AM	Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022 (GlobeNewswire)
Sep-30-22 01:20PM	Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate (Zacks)
10:22AM	Those who invested in Morphic Holding (NASDAQ:MORF) three years ago are up 66% (Simply Wall St.)
Sep-29-22 12:00PM	EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster (Zacks)
10:15AM	Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last? (Zacks)
Sep-28-22 12:00PM	Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree (GlobeNewswire) +7.31%
Sep-27-22 12:46PM	Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids (Zacks) +6.22%
Sep-26-22 12:39PM	Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why (Zacks)
11:17AM	AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication (Zacks)
Sep-23-22 11:14AM	Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris (Zacks)
11:02AM	Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK (Zacks)
Sep-22-22 01:28PM	Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors (Zacks)
Sep-21-22 11:44AM	AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID (Zacks)
07:00AM	Morphic Celebrates Foundational Integrin Research Published in Cell (GlobeNewswire)
Sep-20-22 12:10PM	AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication (Zacks)
Sep-19-22 12:28PM	Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia (Zacks)
12:21PM	Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids (Zacks)
Sep-16-22 11:42AM	Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal (Zacks)
Sep-15-22 12:15PM	J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up (Zacks)
11:54AM	Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine (Zacks)
Sep-14-22 01:33PM	Key Factors Driving Merck's (MRK) Outperformance This Year (Zacks)
01:09PM	Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer (Zacks)
Sep-13-22 11:24AM	FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill (Zacks) -5.68%
Sep-12-22 12:24PM	Stifel Sees S&P 500 at 4,400 by Years End; Here Are 2 Stocks to Play the Rebound (TipRanks)
Sep-09-22 12:23PM	Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug (Zacks)
Sep-08-22 09:37AM	Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag (Zacks)
Sep-07-22 11:40AM	GSK's NDA for Daprodustat to be Reviewed by an FDA Panel (Zacks) +5.16%
Sep-06-22 11:09AM	AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer (Zacks)
10:34AM	CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth (Zacks)
Sep-05-22 01:05PM	Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers (Zacks)
Sep-01-22 08:00AM	Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference (GlobeNewswire) +5.38%
Aug-31-22 10:47AM	AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment (Zacks)
Aug-30-22 11:38AM	Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag (Zacks)
Aug-29-22 11:37AM	Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab (Zacks)
Aug-26-22 01:21PM	Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6% (Zacks) -8.62%

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLATTERY JOSEPH P	Director	Nov 13	Buy	20.60	2,400	49,436	9,066	Nov 14 07:04 PM
Edwards Martin	Director	Nov 13	Buy	20.54	2,376	48,803	2,376	Nov 15 07:00 PM
SCHEGERIN MARC	CFO and COO	Sep 07	Option Exercise	15.00	20,000	300,000	44,136	Sep 08 07:00 PM
SCHEGERIN MARC	CFO and COO	Sep 07	Sale	54.34	20,000	1,086,849	24,136	Sep 08 07:00 PM
Tipirneni Praveen P.	President and CEO	Aug 01	Option Exercise	4.32	3,597	15,539	17,533	Aug 03 06:58 PM
Tipirneni Praveen P.	President and CEO	Aug 01	Sale	57.04	3,597	205,187	13,936	Aug 03 06:58 PM
Tipirneni Praveen P.	President and CEO	Jul 03	Option Exercise	4.32	3,597	15,539	17,533	Jul 06 07:02 PM
Tipirneni Praveen P.	President and CEO	Jul 03	Sale	57.04	3,597	205,178	13,936	Jul 06 07:02 PM
Tipirneni Praveen P.	President and CEO	Jun 12	Option Exercise	4.32	840	3,629	14,776	Jun 14 07:04 PM
Tipirneni Praveen P.	President and CEO	Jun 12	Sale	63.01	840	52,929	13,936	Jun 14 07:04 PM
DeVaul William	General Counsel and Secretary	Jun 07	Sale	60.05	7,756	465,742	13,338	Jun 09 07:00 PM
Tipirneni Praveen P.	President and CEO	Jun 01	Option Exercise	4.32	3,597	15,539	17,533	Jun 02 07:01 PM
Tipirneni Praveen P.	President and CEO	Jun 01	Sale	57.14	3,597	205,519	13,936	Jun 02 07:01 PM
DeVaul William	General Counsel and Secretary	May 24	Sale	60.00	100	6,000	21,094	May 25 08:44 PM
Farrell Robert E Jr	SVP Finance and CAO	May 23	Option Exercise	4.32	10,000	43,200	33,708	May 25 08:45 PM
Farrell Robert E Jr	SVP Finance and CAO	May 23	Sale	60.00	10,000	600,000	23,708	May 25 08:45 PM
DeVaul William	General Counsel and Secretary	May 23	Sale	60.03	3,802	228,236	21,194	May 25 08:44 PM
Farrell Robert E Jr	SVP Finance and CAO	May 08	Option Exercise	4.32	11,486	49,620	23,708	May 10 07:02 PM
Rogers Bruce	President	May 05	Option Exercise	4.32	16,000	69,042	133,055	May 09 07:03 PM
Tipirneni Praveen P.	President and CEO	May 03	Option Exercise	4.32	3,597	15,539	17,533	May 05 07:15 PM
SPRINGER TIMOTHY A	Director	May 03	Buy	45.00	1,050,000	47,250,000	2,768,464	May 04 07:06 PM
Tipirneni Praveen P.	President and CEO	May 03	Sale	51.11	3,597	183,857	13,936	May 05 07:15 PM
SCHEGERIN MARC	CFO and COO	Apr 25	Option Exercise	15.00	50,000	750,000	74,136	Apr 27 07:03 PM
Rogers Bruce	President	Apr 25	Option Exercise	4.32	30,000	129,453	147,055	Apr 27 07:02 PM
Tipirneni Praveen P.	President and CEO	Apr 25	Option Exercise	4.32	25,179	108,773	39,115	Apr 27 07:04 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 25	Option Exercise	4.32	10,000	43,200	22,222	Apr 27 07:05 PM
SCHEGERIN MARC	CFO and COO	Apr 25	Sale	54.71	50,000	2,735,500	24,136	Apr 27 07:03 PM
Rogers Bruce	President	Apr 25	Sale	53.40	30,000	1,602,129	117,055	Apr 27 07:02 PM
Tipirneni Praveen P.	President and CEO	Apr 25	Sale	53.40	25,179	1,344,667	13,936	Apr 27 07:04 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 25	Sale	54.71	10,000	547,100	12,222	Apr 27 07:05 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 20	Option Exercise	4.32	10,000	43,200	22,222	Apr 21 07:01 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 20	Sale	45.00	10,000	450,000	12,222	Apr 21 07:01 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 19	Option Exercise	4.32	10,000	43,200	12,222	Apr 19 07:06 PM
Rogers Bruce	President	Apr 17	Option Exercise	4.32	10,000	43,151	127,055	Apr 19 07:06 PM
Farrell Robert E Jr	SVP Finance and CAO	Apr 17	Sale	41.25	20,000	825,001	2,222	Apr 19 07:06 PM
Rogers Bruce	President	Apr 17	Sale	40.35	10,000	403,463	117,055	Apr 19 07:06 PM
SCHEGERIN MARC	CFO and COO	Mar 09	Option Exercise	15.00	6,666	99,990	23,740	Mar 09 06:59 PM
SCHEGERIN MARC	CFO and COO	Mar 07	Option Exercise	15.00	50,000	750,000	67,074	Mar 09 06:59 PM
SCHEGERIN MARC	CFO and COO	Mar 07	Sale	45.00	50,000	2,250,050	17,074	Mar 09 06:59 PM
Rogers Bruce	President	Feb 14	Option Exercise	4.32	10,000	43,200	126,192	Feb 16 07:01 PM
Rogers Bruce	President	Feb 14	Sale	40.09	10,000	400,901	116,192	Feb 16 07:01 PM
Tipirneni Praveen P.	President and CEO	Jan 14	Sale	30.63	4,027	123,338	12,679	Jan 18 07:05 PM
Rogers Bruce	President	Jan 14	Sale	30.63	1,778	54,458	116,192	Jan 18 07:07 PM
SCHEGERIN MARC	CFO and COO	Jan 14	Sale	30.63	1,670	51,150	16,212	Jan 18 07:06 PM
Farrell Robert E Jr	SVP Finance and CAO	Jan 14	Sale	30.63	1,248	38,224	22,222	Jan 18 07:08 PM
DeVaul William	General Counsel and Secretary	Jan 14	Sale	30.63	1,169	35,805	23,739	Jan 18 07:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MORF

Morphic Holding Inc

Upgrade your FINVIZ experience